Today
+2.39%
5 Days
+3.43%
1 Month
+16.44%
6 Months
+9.43%
Year to Date
+2.51%
1 Year
+28.93%
• Thermo Fisher exceeded quarterly earnings estimates and raised full-year organic revenue guidance. • Increased pharmaceutical capital expenditure and demand for clinical services boosted the company's backlog. • Technical indicators suggest a buy signal with an average analyst price target of $634.52.
• Stryker exceeded second-quarter earnings expectations driven by strong MedSurg and Neurotechnology segment performance. • Management raised full-year organic growth and earnings guidance following higher elective procedure volumes. • Analyst upgrades and increased institutional demand contributed to positive momentum in Stryker shares.
• Stryker’s second-quarter earnings exceeded analyst expectations with growth in MedSurg and Neurotechnology. • Management raised full-year earnings guidance citing strong demand and elective procedure recovery. • Analysts increased price targets following positive performance and consistent robotic technology market expansion.
• Danaher’s quarterly earnings surpassed analyst expectations, driving a rise in the company’s stock price. • Bioprocessing demand has normalized, signaling a recovery in the company’s biotechnology and life sciences segments. • Management raised full-year earnings and revenue guidance, citing sustainable growth in core business units.
• Thermo Fisher Q2 2026 results exceeded expectations amid bioprocessing recovery and inventory normalization. • Management raised full-year earnings guidance following strong growth in clinical research and diagnostics. • Analysts issued multiple buy ratings with an average price target of $603.15.
• UnitedHealth reported strong quarterly earnings driven by growth in its Optum health services segment. • Stable Medicare Advantage reimbursement rates have improved sentiment toward the managed care sector. • A resilient labor market and cooling inflation are supporting UnitedHealth's commercial insurance revenue.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.53% |
| BlackRock Institutional Trust Company, N.A. | 4.71% |
| State Street Investment Management (US) | 4.47% |
| Capital World Investors | 2.96% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 53.12% |
| Investment Advisor/Hedge Fund | 29.79% |
| Research Firm | 2.97% |
| Pension Fund | 2.82% |
Related Instruments
Popular Instruments